Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study

A W Blackstock, F Mornex, C Partensky, L Descos, L D Case, S A Melin, E A Levine, G Mishra, S A Limentani, L A Kachnic, J E Tepper, A W Blackstock, F Mornex, C Partensky, L Descos, L D Case, S A Melin, E A Levine, G Mishra, S A Limentani, L A Kachnic, J E Tepper

Abstract

The safety and efficacy of gemcitabine and concurrent radiation to the upper abdomen followed by weekly gemcitabine in patients with resected pancreatic cancer was determined. Patients with resected adenocarcinoma of the pancreas were treated with intravenous gemcitabine administered twice-weekly (40 mg m(-2)) for 5 weeks concurrent with upper abdominal radiation (50.4 Gy in 5(1/2) weeks). At the completion of the chemoradiation, patients without disease progression were given gemcitabine (1000 mg m(-2)) weekly for two cycles. Each cycle consisted of 3 weeks of treatment followed by 1 week without treatment. Forty-seven patients were entered, 46 of whom are included in this analysis. Characteristics: median age 61 years (range 35-79); 24 females (58%); 73% stage T3/T4; and 70% lymph node positive. Grade III/IV gastrointestinal or haematologic toxicities were infrequent. The median survival was 18.3 months, while the median time to disease recurrence was 10.3 months. Twenty-four percent of patients were alive at 3 years. Only six of 34 patients with progression experienced local regional relapse as a component of the first site of failure. These results confirm the feasibility of delivering adjuvant concurrent gemcitabine and radiation to the upper abdomen. This strategy produced good local regional tumour control.

Figures

Figure 1
Figure 1
Overall and recurrence free survival.

References

    1. Allen AM, Zalupski MM, Robertson JM, Eckhauser FE, Simone D, Brown D, Hejna G, Normolle D, Lawrence TS, McGinn CJ (2004) Adjuvant therapy in pancreatic cancer: phase I trial of radiation dose escalation with concurrent full-dose gemcitabine. Int J Radiat Oncol Biol Phys 59: 1461–1467
    1. Blackstock AW, Bernard SA, Richards F, Eagle KS, Case LD, Poole ME, Savage PD, Tepper JE (1999) Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol 17: 2208–2212
    1. Blackstock AW, Lightfoot H, Case LD, Tepper JE, Mukherji SK, Mitchell BS, Swarts SG, Hess SM (2001) Tumor uptake and elimination of 2′,2′-difluoro-2′-deoxycytidine (gemcitabine) after deoxycytidine kinase gene transfer: correlation with in vivo tumor response. Clin Cancer Res 7: 3263–3268
    1. Blackstock AW, Tepper JE, Niedwiecki D, Hollis DR, Mayer RJ, Tempero MA (2004) Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer 34: 107–116
    1. Boven E, Schipper H, Erkelens CA, Hatty SA, Pinedo HM (1993) The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer. Br J Cancer 68: 52–56
    1. Burris III HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial (see comments). J Clin Oncol 15: 2403–2413
    1. Carmichael J, Fink U, Russell RC, Spittle MF, Harris AL, Spiessi G, Blatter J (1996) Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 73: 101–105
    1. Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, Trochanowski B, Tarassoff PG (1994) Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12: 29–34
    1. Crane CH, Janjan NA, Evans DB, Wolff RA, Ballo MT, Milas L, Mason K, Charnsangavej C, Pisters PW, Lee JE, Lenzi R, Vauthey JN, Wong A, Phan T, Nguyen Q, Abbruzzese JL (2001) Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Int J Pancreatol 29: 9–18
    1. Eisbruch A, Shewach DS, Bradford CR, Littles JF, Teknos TN, Chepeha DB, Marentette LJ, Terrell JE, Hogikyan ND, Dawson LA, Urba S, Wolf GT, Lawrence TS (2001) Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study. J Clin Oncol 19: 792–799
    1. Fields MT, Eisbruch A, Normolle D, Orfali A, Davis MA, Pu AT, Lawrence TS (2000) Radiosensitization produced in vivo by once- vs twice-weekly 2′2′-difluoro-2′-deoxycytidine (gemcitabine). Int J Radiat Oncol Biol Phys 47: 785–791
    1. Gandhi V, Plunkett W (1990) Modulatory activity of 2′,2′-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res 50: 3675–3680
    1. Gastrointestinal Tumor Study Group (1987) Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 59: 2006–2010
    1. Grunewald R, Abbruzzese JL, Tarassoff P, Plunkett W (1991) Saturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 27: 258–262
    1. Joensuu TK, Kiviluoto T, Karkkainen P, Vento P, Kivisaari L, Tenhunen M, Westberg R, Elomaa I (2004) Phase I–II trial of twice-weekly gemcitabine and concomitant irradiation in patients undergoing pancreaticoduodenectomy with extended lymphadenectomy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 60: 444–452
    1. Joschko MA, Webster LK, Groves J, Yuen K, Palatsides M, Ball DL, Millward MJ (1997) Enhancement of radiation-induced regrowth delay by gemcitabine in a human tumor xenograft model. Radiat Oncol Invest 5: 62–71
    1. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, Arnaud JP, Gonzalez DG, de Wit LT, Hennipman A, Wils J (1999) Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region. Phase III trial of the EORTC GITCCG. Ann Surg 230: 776–784
    1. Lawrence TS, Chang EY, Hahn TM, Hertel LW, Shewach DS (1996) Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine. Int J Radiat Oncol Biol Phys 34: 867–872
    1. Lawrence TS, Chang EY, Hahn TM, Shewach DS (1997) Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2′,2′-difluoro-2′-deoxycytidine (Gemcitabine). Clin Cancer Res 3: 777–782
    1. Lawrence TS, Eisbruch A, McGinn CJ, Fields MT, Shewach DS (1999) Radiosensitization by gemcitabine. Oncology (Huntington) 13: 55–60
    1. Martenson JA, Vigliotti AP, Pitot HC, Geeraerts LH, Sargent DJ, Haddock MG, Ghosh C, Keppen MD, Fitch TR, Goldberg RM (2003) A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 1(55): 1305–1310
    1. Mason KA, Milas L, Hunter NR, Elshaikh M, Buchmiller L, Kishi K, Hittelman K, Ang KK (1999) Maximizing therapeutic gain with gemcitabine and fractionated radiation. Int J Radiat Oncol Biol Phys 44: 1125–1135
    1. McGinn CJ, Zalupski MM, Shureiqi I, Robertson JM, Eckhauser FE, Smith DC, Brown D, Hejna G, Strawderman M, Normolle D, Lawrence TS (2001) Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 19: 4202–4208
    1. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Berger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Buchler MW (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350: 1200–1210
    1. Neuhaus P, Oettle H, Post S, Gellert K, Ridwelski K, Schramm H, Zülke C, Fahlke J, Langrehr H, Riess H (2005) A randomized, prospective, multicenter, phase III trial of adjuvant chemotherapy with gemcitabine vs observation in patients with resected pancreatic cancer. ASCO Annual Meeting Proceedings 23, 16S, #4013
    1. Pipas JM, Mitchell SE, Barth RJJ, Vera-Gimon R, Rathmann J, Meyer LP, Wagman RS, Lewis LD, McDonnell C, Colacchio TA, Perez RP (2001) Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 50: 1317–1322
    1. Shewach DS, Hahn TM, Chang E, Hertel LW, Lawrence TS (1994) Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res 54: 3218–3223
    1. Shewach DS, Lawrence TS (1995) Radiosensitization of human tumor cells by gemcitabine in vitro. Semin Oncol 22: 68–71
    1. Shewach DS, Lawrence TS (1996) Radiosensitization of human solid tumor cell lines with gemcitabine. Semin Oncol 23: 65–71
    1. Talamonti MS, Catalano PJ, Vaughn DJ, Whittington R, Beauchamp RD, Berlin J, Benson III AB (2000) Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity. J Clin Oncol 18: 3384–3389
    1. Van Laethem J-L, Demols A, Gay F, Closon MT, Colette M, Polus M, Houbiers G, Gastelblum P, Gelin M, Houtte PV, Closset J (2003) Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: a phase II study. Int J Radiat Oncol Biol Phys 56: 974–980
    1. Wolff RA, Evans DB, Gravel DM, Lenzi R, Pisters PW, Lee JE, Janjan NA, Charnsangavej C, Abbruzzese JL (2001) Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res 7: 2246–2253
    1. Yavuz AA, Aydin F, Yavuz MN, Ilis E, Ozdemir F (2001) Radiation therapy and concurrent fixed dose amifostine with escalating doses of twice-weekly gemcitabine in advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 51: 974–981

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit